Reply to “Peritoneal carcinomatosis in patients with gastric cancer and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy”

Hyperthermic intraperitoneal chemotherapy (HIPEC) has been demonstrated to be prophylactic against peritoneal recurrence and to result in improved survival.6 Thus, gastric cancer patients with positive peritoneal cytology who do not have a macroscopic peritoneal disease but an occult carcinomatosis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of surgery 2014-07, Vol.208 (1), p.158-159
Hauptverfasser:	Graziosi, Luigina, MD, PhD, Marino, Eliabetta, MD, Donini, Annibale, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cellular biology Chemotherapy Chemotherapy, Cancer, Regional Perfusion Female Gastric cancer Humans Hyperthermia, Induced Male Medical prognosis Ovarian cancer Palliative care Peritoneal Neoplasms - therapy Stomach Neoplasms - pathology Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Hyperthermic intraperitoneal chemotherapy (HIPEC) has been demonstrated to be prophylactic against peritoneal recurrence and to result in improved survival.6 Thus, gastric cancer patients with positive peritoneal cytology who do not have a macroscopic peritoneal disease but an occult carcinomatosis need an integrated multimodal management with surgery, chemotherapy, and, in selected cases, HIPEC.
ISSN:	0002-9610 1879-1883
DOI:	10.1016/j.amjsurg.2013.12.005